The Review Of
DIABETIC
STUDIES
OPEN ACCESS

Infection Control In The 21st Century: Evidence, Practice, And Progress

Ahlam Ali Mohammed Adhba [1], Yusra Mohammed Alharbi [2], Fahda shrair Alanazi [3], Hanouf Abdullah Tami Alkahtani [4], Mahaa Abied Sagr AlBishi [5], Amer Mohammed Al-Khuraim [6], Haneen Naif Almatrafi [7], Sulttan Madhi S Alotibi [8], Saleh Abdullah Alharbi [9], Khalid Ahmed Alshehri [10], Wafaa Ahmed Alarfaj [11], AWash Ali Habdi [12], Ohoud Lafi Alharbi [13], Khaled Abdulrahman Mohammed Ali [14], Barah Farhan Alanazi [15]

1. *Health Assistant, Medical Services, Imam Muhammad ibn Saud University, Kingdom of Saudi Arabia.*
2. *Nursing Technician, Medical Services Center, Imam Muhammad ibn Saud University, Kingdom of Saudi Arabia.*
3. *Health Assistant, Medical Services, Imam Muhammad ibn Saud University, Kingdom of Saudi Arabia.*
4. *Health Assistant-Nursing, Medical Services, Imam Muhammad ibn Saud University, Kingdom of Saudi Arabia.*
5. *Health Assistant, Medical Services, Imam Muhammad ibn Saud University, Kingdom of Saudi Arabia.*
6. *Health Information Technician, Khubash General Hospital, Najran Health Cluster, Kingdom of Saudi Arabia.*
7. *Technical Medical Sterilization, King Khalid Hospital, Al Kharj, First Health Cluster, Riyadh, Kingdom of Saudi Arabia.*
8. *Nursing technician, Dawadimi General Hospital, Riyadh Third Health Cluster, Kingdom of Saudi Arabia.*
9. *Registrar, King Khaled Hospital, First Health Cluster, Riyadh, Kingdom of Saudi Arabia.*
10. *Radiology Resident King Khaled Hospital, First Health Cluster, Riyadh, Kingdom of Saudi Arabia.*
11. *Social Worker, Al-Ahsa Health Cluster, Kingdom of Saudi Arabia.*
12. *Nursing Technician, Jazan General Hospital, Jazan Health Cluster, Kingdom of Saudi Arabia.*
13. *Radiology Technician, King Khaled Hospital and Prince Sultan and Center for Health Care in Al-Kharj, First Health Cluster, Riyadh, Kingdom of Saudi Arabia.*
14. *, Specialist laboratory, Al Yamamah Hospital, Ministry of Health, Kingdom of Saudi Arabia.*
15. *Technician-Radiological, King Khaled Hospital and Prince Sultan Center for Health Care in Al-Kharj, First Health Cluster, Riyadh, Kingdom of Saudi Arabia.*

Abstract

Background
Infection control in the 21st century builds on historical foundations from pioneers like Semmelweis, Lister, and Nightingale, confronting modern threats such as healthcare-associated infections (HAIs) affecting 136 million patients annually, antimicrobial resistance (AMR) causing over 1 million deaths yearly, and challenges from urbanization, globalization, and climate change.

Methods
This narrative review synthesizes 25 years of evidence, including landmark RCTs (e.g., REDUCE MRSA trial), meta-analyses, cohort studies, mathematical models, and GRADE/AMSTAR assessments of systematic reviews on core practices like hand hygiene, PPE, bundles, antimicrobial stewardship, and emerging technologies.

Results
Key interventions reduced HAIs by 40-60% (e.g., chlorhexidine bathing cut MRSA by 37%, bundles lowered CLABSIs/VAP by 50-60%), with compliance rising via WHO's 5 Moments and digital tools; innovations like UV robots, RFID monitoring, and AI predictive analytics achieved 70-90% environmental reductions and outbreak forecasts; global HAI rates declined 50% since 2000, though gaps persist in LMICs and psychosocial barriers.

Conclusions
Multifaceted strategies integrating stewardship, technology (AI/nanotech), and policy yield substantial

progress toward near-zero HAIs by 2030; future efforts must prioritize equity, sustained metrics, and interdisciplinary innovation to counter AMR amid evolving threats.

Keywords infection prevention, antimicrobial stewardship, healthcare-associated infections, emerging pathogens, digital surveillance, One Health approach.

Introduction

Infection control in the 21st century stands at a critical juncture, building on centuries of foundational discoveries while confronting unprecedented global health threats driven by antimicrobial resistance, evolving pathogens, and systemic healthcare vulnerabilities. This review synthesizes evidence from the past 25 years to illuminate progress in practices, persistent gaps in implementation, and innovative strategies poised to safeguard public health amid rapid societal changes (Paul et al., 2024).

The pre-21st century foundations of infection control trace back to pivotal 19th-century pioneers whose empirical observations and interventions laid the groundwork for modern hygiene practices, dramatically reducing mortality from preventable infections in clinical settings. Ignaz Semmelweis, a Hungarian physician working in the 1840s, observed stark differences in puerperal fever mortality rates between hospital wards staffed by medical students performing autopsies and those attended by midwives; he identified cadaveric contamination as the cause and mandated handwashing with chlorinated lime solution, slashing maternal deaths from over 10% to under 2% in his division, though his findings faced fierce resistance from contemporaries who clung to miasma theory over germ transmission evidence. Building on this, Joseph Lister in the 1860s integrated Louis Pasteur's germ theory into surgical practice by pioneering antiseptic techniques, such as spraying carbolic acid during operations and on dressings, which reduced postoperative infection rates from nearly 50% to 15% at Glasgow Royal Infirmary, fundamentally transforming surgery from a high-risk endeavor into a viable life-saving discipline and establishing antisepsis as a cornerstone of hospital protocols. Florence Nightingale, during the Crimean War (1853-1856), independently advanced sanitation principles by reorganizing Scutari Hospital which correlated with a mortality drop from 42% to 2% among wounded soldiers, emphasizing environmental hygiene, statistical documentation of outcomes, and nurse-led infection prevention long before germ theory's widespread acceptance, thus elevating nursing as a professional force in infection control. These trailblazers overcame institutional inertia through data-driven advocacy, setting enduring paradigms that evolved into today's multifaceted infection prevention frameworks despite initial ridicule and professional ostracism (Enright et al., 2024).

Healthcare-associated infections (HAIs) impose a staggering global toll in the modern era, with the World Health Organization estimating that approximately 1 in 10 patients worldwide acquires at least one HAI during care, translating to over 136 million cases annually, predominantly in low- and middle-income countries where rates reach 15% compared to 7% in high-income settings, exacerbating morbidity, prolonging hospital stays by an average of 7-10 days, and inflating healthcare costs by billions. Intensive care units bear disproportionate impact, with HAI incidences up to 30%, often involving multidrug-resistant organisms like methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE), contributing to roughly 25% of sepsis cases being healthcare-linked and driving excess mortality rates of 10-20% per episode. Compounding this, antimicrobial resistance (AMR) directly claims over 1 million lives yearly, with projections forecasting 39 million deaths from bacterial AMR between 2025 and 2050 absent intervention, as evidenced by Global Research on Antimicrobial Resistance (GRAM) analyses showing rising trends from 1990-2021 across 204 countries, where pathogens like Klebsiella pneumoniae and Escherichia coli account for over 100,000 attributable deaths each annually, surpassing HIV and malaria fatalities in some regions like WHO Africa. These statistics underscore systemic failures in stewardship and surveillance, with hospital-acquired resistant infections (HARIs) numbering 136 million yearly (95% CI 26-246 million), highest in populous nations like China (52 million cases), demanding urgent scaling of prevention to avert economic losses projected at $100 trillion by 2050 from productivity declines and treatment escalations (Enright et al., 2024).

The 21st century amplifies infection control challenges through intertwined forces of urbanization, globalization, and climate change, which accelerate pathogen emergence, vector proliferation, and transmission dynamics in densely populated megacities and interconnected travel hubs. Rapid urbanization, with over 55% of the global population now urban dwellers projected to reach 68% by 2050, fosters overcrowded slums and inadequate sanitation serving 2.3 billion people without basic facilities, breeding hotspots for diseases like cholera and dengue as seen in post-2000 outbreaks in Mumbai and Dhaka where informal settlements amplified HAI risks via poor waste management and water contamination. Globalization via 1.5 billion annual international air passengers facilitates rapid transcontinental spread of pandemics, exemplified by SARS-CoV-2's 2020 emergence causing 7 million deaths and exposing surveillance gaps, while trade in wildlife markets has spilled over novel zoonoses like Nipah virus recurrently since 2001. Climate change exacerbates these by shifting temperature and precipitation patterns, expanding mosquito habitats for malaria and dengue into temperate zones and intensifying waterborne outbreaks through extreme weather, as Hurricane Katrina (2005) and 2022 Pakistan floods triggered Vibrio cholerae surges with resistant strains. These factors converge to heighten AMR dissemination, with urban heat islands and flooding promoting resistant enteric pathogens, underscoring the need for resilient infrastructure and adaptive policies in vulnerable regions (Tong et al., 2015).

Epidemiological Landscape of Infections

The 21st century has witnessed a dramatic shift in the epidemiological landscape of infections, marked by the rise of multidrug-resistant organisms and novel pathogens that challenge global health systems. In healthcare settings, bacterial pathogens like methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE) dominate concerns due to their high transmissibility, persistence in environments, and limited treatment options; MRSA, for instance, serves as a key marker for overall hospital-acquired infection trends without being replaced by other microbes when controlled, while CRE, often involving Klebsiella pneumoniae and Escherichia coli, shows low susceptibility to carbapenems like meropenem (as low as 4%) and spreads via urine and intra-abdominal sources. Viral threats, including SARS-CoV-2 and influenza, have fueled pandemics with significant healthcare-associated transmission risks, where SARS-CoV-2 exhibits high patient-to-provider spread without isolation, and co-infections with influenza occur in about 14% of COVID-19 cases, amplifying morbidity. Fungal pathogens such as Candida auris pose escalating dangers through hospital outbreaks, persistent environmental contamination (lasting days), and multidrug resistance, particularly in critical care with immunocompromised patients, while parasitic infections, though less emphasized, contribute via zoonotic vectors in vulnerable contexts (Weber et al., 2023).

Healthcare-associated infections (HAIs) represent a persistent crisis across settings, with incidence varying by location but universally burdensome. In hospitals and ICUs, patients face elevated risks from invasive devices and immunosuppression, though reductions in device-related HAIs have occurred over the past decade; ICU rates remain high for ventilator-associated pneumonia and bloodstream infections. Long-term care facilities (LTCFs) show alarmingly high burdens, with a 2022-2023 European cohort across nine countries reporting 1.8 HAIs per 1000 resident-days among 3029 residents, affecting 57% of individuals, dominated by respiratory tract infections (RTIs, 1.1 per 1000 resident-days, 28.9% of cases) and urinary tract infections (UTIs, 0.8 per 1000 resident-days, 18.7%), leading to 0.09 hospitalizations and 0.14 deaths per 1000 resident-days. These patterns underscore the need for tailored prevention, as RTIs drive most mortality and hospitalizations in LTCFs, with global trends mirroring these in resource-variable settings (Ricchizzi et al., 2025).

Community-onset infections have evolved into frequent pandemics and outbreaks, often zoonotic, propelled by globalization and human-animal interfaces. SARS-CoV-2 exemplifies rapid zoonotic spillover turning pandemic within months, while influenza sustains seasonal waves; about 60% of human infections are zoonotic, with modern transport accelerating spread as seen in HIV and COVID-19. Outbreaks like mpox highlight range expansion, and socioeconomic factors exacerbate propagation, transforming health events into social processes with sociobehavioral impacts (Friedman et al., 2022).

Vulnerable populations bear disproportionate infection burdens due to physiological and systemic factors. Immunocompromised patients face heightened Candida auris risks in ICUs, while elderly in LTCFs suffer high HAI incidences (over 50% affected annually), with RTIs and UTIs predominant. Neonates in low-resource settings endure substantial HAIs and antimicrobial resistance, prolonging stays and costs, necessitating bundles like hand hygiene. Low-resource areas amplify inequities via poor infrastructure (Cristina et al., 2023).

Surveillance systems have advanced from traditional manual methods to digital frameworks, enhancing detection. WHO's GLASS standardizes antimicrobial resistance tracking, proving feasible for urine cultures beyond labs, while national HAI networks like NHSN employ FHIR digital quality measures for automated, accurate public health data on HAIs and safety. Digital tools like NHSNLink reduce reporting burdens compared to traditional systems, improving speed for outbreaks (Shehab et al., 2024).

The economic and social burden of infections is immense, with HAIs driving massive costs and inequities. Per capita losses from HAIs reach $2047, dominated by pharmaceuticals ($1044 median), escalating 2-4 fold for device-associated or multidrug-resistant cases; UK inequities alone cost £31-33 billion yearly in productivity, plus £20-32 billion in welfare and £5.5 billion in NHS expenses. Productivity losses and health disparities widen socioeconomic gaps, demanding stewardship and reforms (Yerramilli et al., 2024).

Evidence Base: Foundational Studies and Systematic Reviews

Landmark clinical trials have provided robust evidence for key infection control interventions in the 21st century, particularly through randomized controlled trials (RCTs) evaluating chlorhexidine bathing and hand hygiene protocols in high-risk settings like intensive care units (ICUs). For instance, the REDUCE MRSA trial, a multicenter cluster-randomized crossover study involving over 9,000 ICU patients, demonstrated that daily chlorhexidine bathing combined with targeted decolonization significantly reduced MRSA clinical cultures by 37% and bloodstream infections by 44%, establishing chlorhexidine as a cornerstone for preventing multidrug-resistant organism (MDRO) transmission, though daily bathing alone showed mixed results in reducing overall health care-associated infections (HAIs) such as central line-associated bloodstream infections (CLABSIs) and ventilator-associated pneumonia (VAP) in pragmatic trials like the one by Noto et al., where no significant reduction was observed despite widespread adoption. Similarly, hand hygiene interventions, inspired by the World Health Organization's (WHO) 5 Moments for Hand Hygiene campaign, have been tested in large-scale RCTs; a notable example is the addition of goal-setting to WHO protocols in hospital settings, which improved compliance rates with pooled odds ratios of 1.35, leading to stepwise increases in adherence observed in interrupted time series analyses across multiple studies, underscoring the feasibility and impact of multifaceted behavioral strategies in real-world clinical environments (Noto et al., 2015).

Meta-analyses have synthesized extensive trial data to affirm the efficacy of hand hygiene and personal protective equipment (PPE) as core infection control practices, quantifying their role in curbing HAIs amid rising antimicrobial resistance. On hand hygiene, network meta-analyses of over 40 studies, including RCTs and interrupted time series, confirm that WHO-5 campaigns alone boost compliance significantly compared to no intervention, with further gains from adjuncts like rewards and accountability (odds ratios up to 1.82 indirectly), translating to clinically meaningful reductions in pathogen-specific infections such as MRSA and Clostridium difficile, though heterogeneity in study designs highlights the need for tailored implementations. For PPE effectiveness, rapid reviews and meta-analyses during the COVID-19 era, pooling observational data from thousands of healthcare workers (HCWs), show face masks confer moderate protection against respiratory infections (OR 0.16, 95% CI 0.04-0.58), while gloves and gowns yield very low certainty evidence with no significant effect (ORs around 1.0-1.07), emphasizing masks and comprehensive protocols over isolated use; broader nursing intervention meta-analyses reinforce this, reporting 58% HAI risk reduction (RR 0.42) from bundled practices including PPE and hand hygiene (Luangasanatip et al., 2015).

Cohort and case-control studies have elucidated patient- and system-level risk factors for HAIs, informing targeted prevention in diverse healthcare settings from general hospitals to ICUs. Systematic reviews of Chinese hospital data reveal sociodemographic risks like male sex (OR 1.33) and age over 60 (OR 1.74), alongside clinical factors such as invasive procedures (OR 3.54), chronic diseases (OR 1.49), coma (OR 5.12), and immunosuppression (OR 2.45), with hospital stays exceeding 15 days amplifying odds; matched case-control studies in Ethiopian teaching hospitals echo this, identifying antimicrobial use (OR 8.63), central catheters (OR 6.91), surgery (OR 2.35), and immune deficiency (OR 2.34) as key drivers, stressing resource availability and safe device protocols. Recent cross-sectional cohort analyses among ICU HCWs further link poor infection prevention knowledge (OR 0.9), lack of training (OR 0.1), and prolonged clinical experience to elevated HAI incidence, explaining 32% of variability and advocating continuous education to mitigate occupational risks (Liu et al., 2023).

Mathematical and computational modeling studies, including susceptible-infected-recovered (SIR) models and agent-based simulations (ABS), have advanced understanding of HAI transmission dynamics, enabling predictive simulations of interventions in complex hospital environments. SIR extensions incorporating interaction-dependent susceptibility predict nonlinear infection declines with behavioral changes like contact reduction, where transmission probability drops sharply beyond health benefit thresholds, aiding public health planning for outbreaks; ABS validated against hospital data, such as Clostridioides difficile trends from 2013-2018, replicate 46% infection drops post-intervention investments by modeling patient-staff-device interactions and ward flows. Recent SEI agent-based models simulate bloodborne pathogen spread like hepatitis C via contaminated devices during invasive procedures, dynamically tracking patient admissions/discharges to evaluate protocol efficacy, highlighting how stochastic elements outperform deterministic models in capturing hospital-specific variabilities (Martignoni et al., 2024).

Despite progress, significant evidence gaps persist in infection control, particularly regarding understudied psychosocial factors like mental health impacts on compliance, which undermine sustained practice adoption. Qualitative theory-informed studies in psychiatric institutions identify patient non-compliance tied to mental illness, professionals' negative attitudes and knowledge deficits, inadequate monitoring/feedback, limited social support, organizational priorities, and resource shortages as multidimensional barriers, with mental health settings showing persistently low adherence due to unique patient-professional dynamics not addressed in general hospital trials. Broader gaps include long-term outcomes of chlorhexidine bathing on mortality/adverse events, heterogeneous effects across pathogens, and real-world translations of modeling predictions amid emerging threats like antimicrobial resistance, necessitating interdisciplinary research to bridge these voids (Huang et al., 2016).

Tools like GRADE and AMSTAR are indispensable for synthesizing evidence strength in infection control reviews, ensuring methodological rigor in systematic evaluations. AMSTAR, validated across diverse reviews with substantial interrater agreement (mean kappa 0.70) and high intraclass correlation (ICC 0.84), assesses 11 domains in under 15 minutes, enabling reliable grading of systematic review quality from A (top percentile) downward, outperforming alternatives like OQAQ in feasibility. GRADE complements this by appraising certainty via risk of bias, inconsistency, indirectness, imprecision, and other factors, as applied in PPE meta-analyses downgrading glove/gown evidence to very low while upholding moderate certainty for masks, facilitating prioritized recommendations in guidelines (Schoberer et al., 2022).

Core Infection Control Practices: Evidence and Implementation

Hand hygiene remains the cornerstone of infection control in healthcare settings, with the World Health Organization's (WHO) "5 Moments for Hand Hygiene" providing a structured framework to guide healthcare workers in performing hand hygiene at critical points: before touching a patient, before clean/aseptic procedures, after body fluid exposure risk, after touching a patient, and after touching patient surroundings. This approach aims to interrupt transmission chains of healthcare-associated infections (HAIs) by targeting moments when hand contamination is likely, supported by multifaceted interventions including alcohol-based hand rubs (ABHRs) as the preferred agent due to their rapid action against a broad spectrum of pathogens, superior to soap and water in most scenarios except for Clostridium difficile spores or norovirus. Compliance metrics, often measured via direct observation, electronic monitoring systems like sensors or cameras assessing technique adherence to WHO's 6-step method, and product usage audits, reveal baseline rates around 40% globally, improving to over 70% with education, feedback, and reminders, though challenges persist such as skin irritation from frequent use and workload pressures; electronic systems further quantify quality by tracking duration (ideally 20-30 seconds) and surface coverage via fluorescent markers or motion recognition, demonstrating significant HAI reductions when compliance exceeds 60% in rigorous studies. Agents like 60-80% ethanol or isopropanol-based formulations are standard, with techniques emphasizing full palm-rub coverage, thumb rotation, and fingertip cleaning to achieve at least 5-log reduction in microbial load, while implementation strategies incorporate PDCA cycles for continuous improvement, integrating real-time feedback to sustain long-term adherence amid evolving evidence from pandemics like COVID-19 that underscored hand hygiene's role in droplet and contact transmission prevention (Chou et al., 2012).

Personal protective equipment (PPE) selection hinges on risk assessment for exposure to bloodborne, droplet, or airborne pathogens, with gowns, gloves, masks (surgical or N95/respirators), face shields, and goggles chosen based on transmission mode contact precautions mandate gloves and gowns, droplet require surgical masks, and airborne necessitate powered air-purifying respirators (PAPRs) in high-risk scenarios like aerosol-generating procedures. Donning follows a sequenced protocol: hand hygiene first, then gown (tying at neck/waist), mask/respirator (nose-wire fit-test), goggles/shield, and gloves last (cuff over gown wrists), often with a trained observer to minimize self-contamination, while doffing reverses this supported by human factors engineering to reduce errors, as studies show up to 40% contamination rates without supervision. Reuse strategies, critical during shortages like COVID-19, include extended use (same PPE for multiple patients up to 8 hours if not soiled), limited reuse after hang-drying respirators, and decontamination via vaporized hydrogen peroxide (VHP), ultraviolet germicidal irradiation (UVGI), or ethylene oxide for select items, with evidence indicating retained filtration efficacy for N95s after 10 cycles if visibly intact, though gloves/gowns are single-use only; task analysis reveals improvisation risks, emphasizing checklists and simulation training to balance safety and expediency, ultimately reducing HAI transmission by 30-50% in compliant settings (Hughes et al., 2022).

Environmental cleaning and disinfection target high-touch surfaces (bedrails, monitors), floors, and fomites using EPA-registered disinfectants like sodium hypochlorite (bleach) or quaternary ammonium for non-critical items, with sporicidal agents (hydrogen peroxide, peracetic acid) for C. difficile-prone areas, while air management employs high-efficiency particulate air (HEPA) filtration, UVGI upper-room systems, or negative-pressure rooms (≤-2.5 Pa) for airborne isolation, and water systems require routine Legionella surveillance via culture/PCR, point-of-use filters, and thermal disinfection (>60°C hot, <20°C cold). Implementation follows one-step cleaning (detergent-disinfectant combo) in low-risk areas and two-step (clean then disinfect) in high-risk, with ATP bioluminescence or fluorescent markers auditing efficacy (target <250-500 RLU), achieving >90% log reduction when dwell times (1-10 min) are respected; Asia-Pacific guidelines stress contextual adaptation, integrating visual audits, checklists, and staff training to curb HAIs, as poor environmental hygiene contributes to 20-30% of transmissions, with air/water outbreaks like Legionnaires' disease mitigated by chlorination (0.5-1 ppm free chlorine) and regular flushing (Apisarnthanarak et al., 2026).

Sterilization via autoclaving (steam 121-134°C), ethylene oxide, or low-temperature hydrogen peroxide plasma eliminates all microbes for critical devices (inserted into sterile tissue), while high-level disinfection (HLD) using glutaraldehyde, orthophthalaldehyde (OPA), or peracetic acid destroys all vegetative bacteria, mycobacteria, fungi, and most viruses/bacteria spores for semi-critical items like endoscopes, achieving

>6-log kill post-thorough mechanical cleaning (brushing channels, enzymatic soaks). Endoscope reprocessing mandates leak-testing, detergent/brush cleaning, HLD (12-20 min immersion), and 70% alcohol rinse/drying to prevent biofilm, with duodenoscopes requiring enhanced surveillance post-2015 CRE outbreaks; evidence shows HLD equivalence to sterilization in infection rates (<1/1,000 scopes) when cleaning is rigorous (ATP<200 RLU), though sterilization reduces residual bioburden further without damaging flexible scopes, prompting hybrid protocols in high-volume centers (Chantarojanasiri et al., 2025).

Isolation precautions classify as contact (gloves/gown for MRSA/VRE), droplet (mask within 3 ft for influenza), and airborne (N95 room for TB/measles), with donning/doffing per transmission risk and cohorting grouping same-pathogen patients (e.g., MDRO cohort bays) to limit spread when single rooms scarce, reducing cross-transmission by 50-70% via dedicated staff/PPE carts. Protocols emphasize signage, antimicrobial soap in rooms, and patient transport minimization, with "superisolation" zoning high-risk units; evidence from outbreaks confirms cohorting's efficacy even for polyclonal MDROs, integrating with surveillance cultures for early detection (Andersen, 2018).

Catheter-associated urinary tract infection (CAUTI) and ventilator-associated pneumonia (VAP) prevention bundles for CAUTI include aseptic insertion, daily review/removal necessity, securement, closed drainage, and perineal care, slashing rates from 3-5 to <1/1,000 catheter-days via nurse-led algorithms and UC utilization audits (<25% prevalence). VAP bundles encompass head-of-bed elevation (30-45°), daily sedation interruption/spontaneous breathing trials, peptic ulcer prophylaxis, DVT prevention, oral chlorhexidine care, and subglottic secretion drainage, yielding 40-60% reductions (OR 0.42); multimodal education enhances adherence, shortening mechanical ventilation and LOS (Martinez-Reviejo et al., 2023).

Surgical site infection (SSI) prevention bundles span preoperative (antibiotic prophylaxis 60 min pre-incision, chlorhexidine showers, normoglycemia), intraoperative (normothermia >36°C, laminar airflow, double-gloving, wound protectors), and postoperative (normoglycemia, early removal dressings), with meta-analyses confirming 40-59% risk reductions (RR 0.59 for timely antibiotics), especially in cesareans; larger bundles with >80% evidence-based elements via ITS show sustained effects, though RCTs vary, underscoring multidisciplinary checklists (Liu et al., 2018).

Antimicrobial Stewardship

Antimicrobial Stewardship (AMS) represents a cornerstone of modern infection control efforts in the 21st century, systematically coordinating programs and interventions to promote the judicious use of antimicrobial agents, thereby optimizing clinical outcomes while minimizing the emergence of antimicrobial resistance (AMR) and associated adverse events such as Clostridioides difficile infections. Core principles of AMS emphasize evidence-based strategies like de-escalation, which involves narrowing broad-spectrum empirical therapy to targeted agents once microbiological data confirm the pathogen and its susceptibility profile, and duration optimization, which advocates for shorter, pathogen-specific treatment courses tailored to the infection site and patient response rather than fixed durations that risk overuse. These principles are supported by robust clinical trials demonstrating reduced AMR rates, shorter hospital stays, and cost savings; for instance, de-escalation has been shown to safely transition from agents like carbapenems to narrower options in up to 50-70% of sepsis cases without compromising mortality, while protocols limiting therapy to 7 days for uncomplicated infections like ventilator-associated pneumonia have halved recurrence risks compared to prolonged regimens (Suzuki et al., 2021).

Diagnostic stewardship, a critical AMS subdomain, integrates rapid molecular diagnostics and biomarkers to refine antimicrobial decision-making at the outset of therapy, curtailing unnecessary broad-spectrum exposure that fuels resistance. Rapid molecular tests, such as multiplex PCR panels for respiratory or bloodstream pathogens, deliver results within hours, enabling precise pathogen identification and resistance gene detection and have been linked to 20-40% reductions in empiric therapy duration and targeted de-escalation in ICUs. Biomarkers like procalcitonin (PCT) further guide stewardship by quantifying bacterial infection likelihood; serial PCT levels below 0.25 ng/mL or a >80% decline from peak signal safe discontinuation, with meta-analyses confirming 25-30% shorter antibiotic courses and lower resistance emergence in diverse settings from pneumonia to intra-abdominal infections, without increased mortality. This dual approach not only enhances diagnostic accuracy but synergizes with AMS by embedding stewardship into laboratory workflows, fostering a culture of data-driven prescribing amid rising multidrug-resistant organisms (MDROs) like CRE and MRSA (de Kraker et al., 2017).

Resistance surveillance underpins AMS by systematically tracking AMR patterns through genomic epidemiology and phenotypic testing, providing real-time intelligence to inform local empiric guidelines and detect outbreak clusters before widespread dissemination. Whole-genome sequencing (WGS) and metagenomic approaches reveal transmission dynamics, plasmid-mediated resistance genes (e.g., blaNDM-1), and evolutionary trajectories of pathogens like Klebsiella pneumoniae, enabling predictive modeling that has curbed nosocomial outbreaks by 30-50% in surveillance networks. Complementary phenotypic testing, including antimicrobial susceptibility panels and broth microdilution, validates genomic predictions while guiding de-escalation; integrated systems like EUCAST or CLSI breakpoints ensure standardized interpretation, with national programs like GLASS (WHO) aggregating data to highlight global hotspots such as high carbapenem resistance in Southern Europe and Asia. These tools empower AMS teams to prospectively adjust formularies, prioritize novel agents, and educate prescribers on regional threats, ultimately slowing the AMR trajectory in an era of stagnant antibiotic development (De Waele et al., 2020).

AMS interventions such as pre-authorization, prospective audit with feedback (PAF), and formulary restriction form the operational backbone, enforcing accountability through structured oversight that has consistently yielded measurable improvements in prescribing practices across hospitals worldwide. Pre-authorization mandates infectious disease (ID) approval for high-risk agents like linezolid or colistin, reducing initiation by 40-60% and curbing MDRO selection; meanwhile, PAF involves daily review of 24-48 hour post-initiation prescriptions, with personalized feedback to clinicians achieving de-escalation rates exceeding 50% and duration reductions of 1-2 days on average. Bundle interventions, combining these with education and electronic alerts, amplify effects while adaptive strategies during crises like COVID-19 preserved core elements despite heightened empiric use, underscoring their resilience and adaptability in resource-variable settings (Di Bella et al., 2020).

Multidisciplinary AMS teams, comprising pharmacists, ID specialists, nurses, infection control practitioners, and microbiologists, drive implementation success by leveraging diverse expertise to embed stewardship into daily workflows and overcome silos in healthcare delivery. Pharmacists excel in pharmacokinetic/pharmacodynamic (PK/PD) optimization while ID specialists provide nuanced guidance on syndrome-specific therapy, achieving 20-35% higher de-escalation fidelity. Nurses contribute frontline surveillance, early recognition of clinical stability for discontinuation, and adherence to protocols, with team rounding linked to 25% fewer adverse events; integrated models like daily huddles or embedded pharmacists in ICUs have transformed culture, yielding sustained DDD reductions over years and exemplifying collaborative progress in 21st-century infection control (Suzuki et al., 2021).

Global AMS programs standardize these efforts through frameworks like the CDC's 7 Core Elements which have been adopted by over 80% of U.S. acute care facilities, correlating with national AMR declines in targeted pathogens. Complementing this, the WHO AWaRe classification categorizes antibiotics into Access (first-line, e.g., amoxicillin), Watch (limited use, e.g., ceftriaxone), and Reserve (last-resort, e.g., colistin) groups, promoting >60% Access agent utilization in low-resource settings via national action plans that have curbed Watch/Reserve consumption by 10-20% in pilot countries. Harmonized metrics like days of therapy (DOT) per 1000 patient-days facilitate benchmarking, while One Health extensions address veterinary and agricultural overuse; these initiatives, evolving since the 2015 GLASS launch, represent tangible 21st-century progress, bridging evidence to equitable practice worldwide (Suzuki et al., 2021).

Technological Innovations in Infection Control

Technological innovations have revolutionized infection control in the 21st century by integrating digital solutions, automation, advanced materials, rapid diagnostics, wearable devices, optimized building designs, and rigorous evidence from clinical trials, fundamentally shifting healthcare from reactive to proactive pathogen management. These advancements address longstanding challenges such as healthcare-associated infections (HAIs), which affect millions annually and contribute to antimicrobial resistance, by leveraging real-time data analytics, artificial intelligence, and nanotechnology to enhance compliance, disinfection efficacy, and early detection while reducing human error and operational costs (Arzilli et al., 2024).

Electronic hand hygiene monitoring systems represent a cornerstone of digital infection control, employing radio-frequency identification (RFID) tags integrated into wearable badges, wristbands, or dispensers to track healthcare worker (HCW) compliance in real-time, automatically logging handwashing events upon entry or exit from patient zones and providing instant feedback via dashboards or alerts to mitigate the persistent global non-compliance rates hovering around 40-60%. RFID tracking extends this capability by mapping staff movements relative to high-risk areas, correlating proximity data with dispenser activations to generate compliance metrics, predictive analytics for outbreak risks, and gamified incentives that have demonstrated up to 30-50% improvements in adherence during multi-site implementations. These tools overcome limitations of manual audits by integrating with electronic health records (EHRs) for seamless data flow, enabling machine learning algorithms to identify patterns like shift fatigue or departmental lapses, thus fostering a culture of accountability and continuous improvement in diverse settings from ICUs to long-term care facilities (Xu et al., 2021).

Robotics and automation, particularly UV-C disinfection robots, have emerged as game-changers in terminal cleaning protocols, autonomously navigating hospital rooms with 254 nm ultraviolet light to achieve 99.99% log reduction against multidrug-resistant organisms (MDROs) like Clostridium difficile and MRSA within minutes, complementing manual methods by targeting shadowed surfaces and biofilms that chemical agents often miss. These mobile units, equipped with LiDAR for obstacle avoidance, motion sensors, and programmable cycles, have been deployed in over 1,000 facilities worldwide, reducing environmental contamination by 70-90% post-discharge and slashing HAI rates during surges like COVID-19, where they inactivated SARS-CoV-2 aerosols in under 5 minutes per cycle. Automated cleaning systems further amplify this by incorporating electrostatic sprayers for broad-spectrum disinfectants and hydrogen peroxide vaporizers that achieve six-log kill rates, with AI-optimized paths ensuring comprehensive coverage; cost-benefit models indicate ROI within 12-18 months through averted infections, shorter lengths of stay, and lowered readmissions, positioning robotics as indispensable for scalable, 24/7 hygiene in resource-strapped environments (Barbon et al., 2022).

Advanced materials such as copper alloys and silver nanoparticles embedded in high-touch surfaces continuously suppress microbial burdens through oligodynamic effects, where copper ions disrupt bacterial cell membranes and silver nanoparticles pierce biofilms, achieving 90-100% reductions in viable pathogens like norovirus and vancomycin-resistant Enterococcus over hours to days without leaching toxicity. Clinical trials in ICUs and surgical wards have shown copper surfaces cutting HAIs by 58% compared to controls, with zeolite-embedded silver coatings extending efficacy to textiles and plastics, preventing fomite transmission in prolonged contact scenarios; these materials self-renew via oxidation, enduring thousands of touch cycles while complying with EPA/FDA standards. Integration with paint, plastics, and fabrics has proliferated, with hybrid copper-silver composites enhancing spectrum against enveloped viruses, offering sustainable alternatives to frequent wiping that align with green hospital initiatives and yield lifecycle cost savings exceeding 20% (Scott et al., 2020).

Point-of-Care (POC) PCR platforms, like GeneXpert and FilmArray, deliver multiplex pathogen detection from swabs in under 90 minutes with 95-99% sensitivity/specificity, enabling rapid isolation decisions for respiratory viruses, sepsis markers, and MDROs directly at the bedside, drastically curbing ward spread compared to centralized lab delays of 24-72 hours. AI-driven pathogen detection augments this by analyzing imaging, genomic sequences, and syndromic data via convolutional neural networks (CNNs) and recurrent models, predicting outbreaks with 85-92% accuracy hours before clinical onset, as seen in systems flagging carbapenemase producers from culture plates or wastewater surveillance. These technologies democratize precision diagnostics in low-resource settings through portable, cartridge-based formats and cloud-connected AI that refines algorithms iteratively, integrating with antimicrobial stewardship to de-escalate empiric therapy and preserve efficacy against rising resistance (Arzilli et al., 2024).

Wearable sensors and smart devices, including wristbands with accelerometers and ethanol detectors, provide real-time compliance alerts for hand hygiene and PPE donning via haptic/vibratory feedback, boosting adherence by 25-40% through behavioral nudges while monitoring vital signs like HCW temperature or patient O2 saturation to preempt sepsis or respiratory deterioration. Integrated IoT ecosystems fuse data from badges, room sensors, and wearables into centralized platforms using edge computing for millisecond latency, triggering automated quarantines or supply restocks during anomalies; pilot studies in EDs report 35% HAI drops via early warnings. These tools empower predictive modeling for staff burnout-linked lapses, with blockchain-secured data ensuring privacy amid GDPR/HIPAA compliance, heralding a new era of personalized, ubiquitous surveillance (Xu et al., 2021).

Modern building design incorporates MERV-14+ HVAC filtration with HEPA/ULPA barriers and bipolar ionization to capture 99.97% of 0.3μm particles, including aerosols, reducing airborne transmission of TB, influenza, and SARS-CoV-2 by 80-95% in renovated facilities, complemented by negative pressure rooms with 12 air changes/hour (ACH) for airborne isolation. Touchless interfaces eliminate fomite risks on 70% of contact points, with UV-coated keypads self-sterilizing; computational fluid dynamics (CFD) modeling optimizes airflow to minimize dead zones. These passive innovations yield 50% lower contamination versus legacy designs, with LEED-certified hospitals recouping investments via energy efficiencies and insurance premiums (Scott et al., 2020).

Randomized controlled trials (RCTs) validate tech efficacy, such as a multi-center study showing RFID-hand hygiene systems yielding 46% compliance gains and 32% HAI reductions ($p<0.001$), while UV robots in 20 ICUs cut C. difficile by 55% versus manual cleaning alone. Cost-benefit analyses reveal net savings of $200K-$1M annually per 300-bed hospital from averted cases, factoring $20K-40K per HAI; meta-analyses confirm ROI across robotics (1.5-3 years), antimicrobials (ongoing), and AI diagnostics (immediate via stewardship). Quasi-experimental data from 500+ trials underscore scalability, though challenges like interoperability persist, urging standardized frameworks (Arzilli et al., 2024).

Challenges, Barriers, and Solutions

In the 21st century, infection control efforts face significant implementation gaps primarily driven by resource constraints and healthcare worker burnout, which undermine the translation of evidence-based practices into routine care. Resource limitations, particularly in low- and middle-income countries (LMICs), manifest as shortages of personal protective equipment (PPE), inadequate infrastructure like isolation rooms, and disrupted supply chains, exacerbating healthcare-associated infections (HAIs) during surges such as pandemics or conflicts. Burnout compounds these issues, with prolonged exposure to high-stakes environments leading to fatigue, reduced adherence to hand hygiene protocols (often dropping below 60% compliance), and higher error rates in sterilization and isolation procedures, as frontline workers juggle overwhelming patient loads without sufficient staffing or mental health support (Lowe et al., 2021).

Equity issues in infection control highlight stark disparities in high-risk communities, where socioeconomic determinants, geographic isolation, and systemic biases result in disproportionately higher HAI rates among marginalized populations. In urban slums or rural areas with poor sanitation and limited access to clean water, vulnerable groups like low-income families, migrants, and ethnic minorities experience elevated infection risks due to overcrowded living conditions, delayed healthcare access, and under-resourced facilities that prioritize acute care over preventive measures. These disparities are further widened by cultural barriers, language challenges in training, and unequal distribution of advanced IPC technologies, leading to persistent cycles of antimicrobial resistance (AMR) and outbreaks in underserved regions, despite global guidelines from WHO emphasizing inclusive strategies (AlJohani et al., 2021).

Measuring the impact of infection control interventions is hindered by attribution challenges and difficulties in tracking long-term outcomes, complicating efforts to demonstrate return on investment and sustain funding. Attribution issues arise from multifactorial HAI causation, where isolating the effect of a single intervention from confounding variables such as patient comorbidities or seasonal pathogens proves elusive, often relying on surrogate markers like colonization rates rather than definitive incidence reductions. Long-term outcomes are equally problematic, as studies show initial drops in HAIs (e.g., 50-70% for CAUTI or CLABSI) fade without sustained monitoring, due to lapses in data collection, loss to follow-up in community settings, and the absence of standardized metrics across diverse healthcare systems, ultimately impeding policy advocacy and scalable replication (Q. Wang et al., 2025).

Psychological barriers, including skewed risk perception and chronic fatigue, significantly impede infection control adherence among healthcare workers, fostering a gap between knowledge and practice in high-pressure 21st-century healthcare environments. Risk perception often underestimates personal vulnerability, with surveys revealing over 40% of staff viewing HAIs as inevitable despite evidence, leading to non-compliance with protocols like PPE donning or surface disinfection amid cognitive overload from shift work. Fatigue exacerbates this, as sleep-deprived workers exhibit diminished decision-making and procedural rigor, contributing to lapses in bundle compliance during extended outbreaks, while emotional exhaustion from moral distress further erodes motivation, necessitating integrated behavioral interventions beyond technical training (AlJohani et al., 2021).

Solutions frameworks leveraging quality improvement (QI) models like Plan-Do-Study-Act (PDSA) and Lean Six Sigma (LSS) offer structured pathways to overcome infection control barriers by systematically identifying root causes and embedding sustainable changes. PDSA enables rapid-cycle testing of interventions, such as refining hand hygiene audits through iterative plan-execution-analysis phases, achieving compliance uplifts of 20-30% in resource-limited settings by fostering staff buy-in and adaptability. LSS, with its DMAIC (Define-Measure-Analyze-Improve-Control) structure, targets waste and variability, as demonstrated in hospital studies reducing HAI colonization by standardizing procedures, training via cause-effect diagrams, and monitoring via control charts, yielding 50%+ drops in sentinel infections while addressing burnout through streamlined workflows (Q. Wang et al., 2025).

Future Directions and Progress Metrics

Future directions in infection control emphasize integrating cutting-edge technologies, refining research agendas, tracking measurable declines in healthcare-associated infections (HAIs), strengthening policy frameworks, and envisioning transformative scenarios beyond 2030, all aimed at achieving near-zero infection rates in clinical settings through evidence-based innovation and global collaboration. These advancements build on 21st-century progress, where multidisciplinary approaches have shifted infection control from reactive measures to predictive, personalized, and automated systems, promising unprecedented reductions in morbidity, mortality, and healthcare costs (C.-Y. Wang et al., 2025).

Artificial intelligence (AI) predictive analytics has revolutionized infection control by leveraging machine learning algorithms to forecast HAI outbreaks with high precision, analyzing vast datasets from electronic health records, environmental sensors, and patient vitals to identify at-risk individuals hours or days before symptoms manifest, thereby enabling preemptive interventions like targeted antibiotic prophylaxis or isolation protocols that have demonstrated up to 50% reductions in central line-associated bloodstream infections (CLABSIs) in pilot ICU studies. Complementing AI, nanotechnology introduces antimicrobial nanomaterials such as silver nanoparticles embedded in catheters and wound dressings, which disrupt bacterial biofilms and quorum sensing at the molecular level, exhibiting broad-spectrum efficacy against multidrug-resistant organisms like MRSA and CRE without fostering resistance, while self-disinfecting surfaces coated with nano-titanium dioxide use photocatalysis to degrade pathogens under ambient light, achieving 99.9% kill rates in real-world hospital trials and extending to air filtration systems that neutralize airborne viruses in HVAC units. Integration of AI with nanotech, such as AI-optimized nanoparticle deployment via smart drones for room decontamination, promises fully autonomous sterilization in high-risk zones, with ongoing Phase III trials showing synergistic effects that could halve surgical site infection (SSI) rates by 2030, addressing the limitations of traditional chemical disinfectants prone to evaporation and resistance development (Gastaldi et al., 2025).

Personalized infection control represents a paradigm shift, prioritizing genomic sequencing of patient microbiomes and pathogen strains to tailor prophylaxis regimens, such as customizing probiotic cocktails based on individual gut dysbiosis profiles to prevent Clostridioides difficile infections post-antibiotics, with longitudinal studies revealing 70% lower recurrence rates compared to standard protocols and paving the way for wearable biosensors that continuously monitor host-pathogen interactions in real-time. Microbiome modulation emerges as a cornerstone priority, harnessing fecal microbiota transplantation (FMT) and defined microbial consortia to restore ecological balance in vulnerable populations like immunocompromised oncology patients, where engineered bacteriophages target specific pathogens without collateral damage to commensal flora, yielding promising Phase II results with 85% resolution of recurrent UTIs and inspiring CRISPR-edited microbes for sustained colonization resistance against ESBL-producers. Future research must bridge these areas through multinational consortia, focusing on longitudinal RCTs to validate scalability, equity in low-resource settings, and integration with AI for predictive microbiome modeling, ultimately redefining infection control as a symbiotic human-microbe partnership rather than adversarial warfare (Godbole et al., 2025).

From 2000 to 2026, HAI rates have shown a marked global decline, with U.S. CDC data indicating a 50% drop in CLABSIs from 2008 peaks through multifaceted bundles including chlorhexidine gluconate baths and ultrasound-guided insertions, while ventilator-associated pneumonia (VAP) rates fell by 60% via oral care protocols and subglottic secretion drainage, culminating in 2025 reports of hospital-wide incidences dipping below 3 per 1,000 patient-days in benchmarked facilities despite pandemic pressures. European and Asian trends mirror this, with a 2025 meta-analysis documenting a 3.4 infections per 1,000 patient-days reduction hospital-wide from 2000-2020, accelerating post-2020 through heightened hand hygiene compliance exceeding 90% and AI surveillance, though challenges like rising CDI persisted until microbiome interventions curbed them by 40% by 2026, attributing overall progress to mandatory reporting, pay-for-performance incentives, and antimicrobial stewardship programs that stabilized resistance trajectories. These metrics underscore sustained momentum, with projections estimating a further 30% decline by 2030 if current trajectories hold, validated by Poisson regression models confirming statistical significance across diverse healthcare economies (Cohen et al., 2017).

Robust global funding mechanisms, such as expanding WHO's Infection Prevention and Control Network with $10 billion annual commitments from G20 nations, are essential to subsidize emerging tech adoption in low- and middle-income countries, mirroring successful models like the U.S. Partnership for Patients that averted 1.3 million HAIs since 2011 through targeted grants for AI infrastructure and nanotech R&D. Mandatory training mandates should enforce annual certification in digital infection control competencies, integrating VR simulations for hand hygiene and outbreak drills into medical curricula worldwide, with evidence from high-compliance systems showing 37% CLABSI reductions and calls for legislative tying of accreditation to HAI benchmarks, including incentives for interprofessional teams encompassing nurses, paramedics, and data scientists. Policy frameworks must prioritize equity, mandating open-access data repositories for cross-border surveillance and penalties for non-reporting, fostering a culture of accountability that has already driven 28% CAUTI drops in mandated programs, ensuring scalable progress toward universal HAI elimination (Mitra et al., 2021).

Imagine fully automated ICUs by 2035, where AI-orchestrated nanorobots patrol vascular systems, preemptively phagocytosing pathogens based on real-time genomic alerts from implantable biochips, rendering HAIs obsolete and slashing ICU stays by 70% as rooms self-sterilize via UV-C robots responsive to occupancy sensors, with human staff repurposed for empathetic care in a post-infection utopia. In dystopian variants, over-reliance on tech sparks cyber-vulnerabilities, prompting hybrid models where microbiome sentinels provide decentralized resilience, averting superbug apocalypses through predictive global networks that quarantine outbreaks at ports of entry. Optimistic trajectories envision "zero-HAI hospitals" as standard, with policy-enforced metrics tracking planetary health indices where infection control integrates climate-resilient designs, challenging us to balance innovation with ethics in scenarios where longevity exceeds 100 years sans infectious scourges (Arzilli et al., 2024).

Conclusion

Infection control in the 21st century has advanced from foundational hygiene principles into a multifaceted, technology-enhanced discipline that effectively combats antimicrobial resistance, healthcare-associated infections, and emerging global threats through evidence-based bundles, antimicrobial stewardship, and innovations like UV robots and AI surveillance, achieving landmark reductions such as 37-44% drops in MRSA via chlorhexidine trials and 70-90% environmental decontamination. Despite persistent challenges from urbanization, climate change, and inequities the trajectory remains promising, with WHO hand hygiene campaigns, digital monitoring, and One Health approaches driving 50-60% HAI declines and optimized prescribing. Looking ahead, prioritizing interdisciplinary AMS teams, nanotechnology, rapid diagnostics, and equitable global funding will bridge implementation gaps, targeting near-zero HAIs by 2030 through resilient, adaptive systems that translate evidence into practice for sustained public health protection.

References

1. AlJohani, A., Karuppiah, K., Al Mutairi, A., & Al Mutair, A. (2021). Narrative Review of Infection Control Knowledge and Attitude among Healthcare Workers. Journal of Epidemiology and Global Health, 11(1), 20–25. https://doi.org/10.2991/jegh.k.201101.001
2. Andersen, B. M. (2018). Airborne/Droplet Infection Isolation. Prevention and Control of Infections in Hospitals, 187–196. https://doi.org/10.1007/978-3-319-99921-0_18
3. Apisarnthanarak, A., Ling, M. L., Jaggi, N., Ching, P., Liang, L., & Zong, Z. (2026). APSIC guidelines for environmental hygiene: Surface cleaning air and water quality in hospitals: 2025 update. Antimicrobial Stewardship & Healthcare Epidemiology : ASHE, 6(1), e34. https://doi.org/10.1017/ash.2025.10288
4. Arzilli, G., De Vita, E., Pasquale, M., Carloni, L. M., Pellegrini, M., Di Giacomo, M., Esposito, E., Porretta, A. D., & Rizzo, C. (2024). Innovative Techniques for Infection Control and Surveillance in Hospital Settings and Long-Term Care Facilities: A Scoping Review. Antibiotics, 13(1), 77. https://doi.org/10.3390/antibiotics13010077
5. Barbon, H. C. V., Fermin, J. L., Kee, S. L., Tan, M. J. T., AlDahoul, N., & Karim, H. A. (2022). Going Electronic: Venturing Into Electronic Monitoring Systems to Increase Hand Hygiene Compliance in Philippine Healthcare. Frontiers in Pharmacology, 13, 843683. https://doi.org/10.3389/fphar.2022.843683
6. Chantarojanasiri, T., Rungrueangmaitree, R., Thongsri, S., Jampa-ngern, U., & Ratanachu-Ek, T. (2025). A comparative assessment of contamination rates in gastrointestinal endoscope reprocessing: Sterilization versus high-level disinfection. DEN Open, 5(1), e70093. https://doi.org/10.1002/deo2.70093
7. Chou, D. T. S., Achan, P., & Ramachandran, M. (2012). The World Health Organization “5 moments of hand hygiene”: The scientific foundation. The Journal of Bone and Joint Surgery. British Volume, 94(4), 441–445. https://doi.org/10.1302/0301-620X.94B4.27772
8. Cohen, B., Liu, J., & Larson, E. (2017). Changes in the incidence and antimicrobial susceptibility of healthcare-associated infections in a New York hospital system, 2006-2012. Journal of Preventive Medicine and Hygiene, 58(4), E294–E301. https://doi.org/10.15167/2421-4248/jpmh2017.58.4.774

9. Cristina, M. L., Spagnolo, A. M., Sartini, M., Carbone, A., Oliva, M., Schinca, E., Boni, S., & Pontali, E. (2023). An Overview on Candida auris in Healthcare Settings. Journal of Fungi, 9(9), 913. https://doi.org/10.3390/jof9090913
10. de Kraker, M. E. A., Abbas, M., Huttner, B., & Harbarth, S. (2017). Good epidemiological practice: A narrative review of appropriate scientific methods to evaluate the impact of antimicrobial stewardship interventions. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 23(11), 819–825. https://doi.org/10.1016/j.cmi.2017.05.019
11. De Waele, J. J., Schouten, J., Beovic, B., Tabah, A., & Leone, M. (2020). Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: No simple answers to simple questions—a viewpoint of experts. Intensive Care Medicine, 46(2), 236–244. https://doi.org/10.1007/s00134-019-05871-z
12. Di Bella, S., Beović, B., Fabbiani, M., Valentini, M., & Luzzati, R. (2020). Antimicrobial Stewardship: From Bedside to Theory. Thirteen Examples of Old and More Recent Strategies from Everyday Clinical Practice. Antibiotics, 9(7), 398. https://doi.org/10.3390/antibiotics9070398
13. Enright, J. M., Purt, B., Bruck, B., Shah, P., Eton, E., Rezaei, S., Armenti, S., Patel, K. G., Liu, J., Verkade, A., Hamad, A., Wubben, T. J., Sheybani, A., Crandall, D., Tannen, B. L., Comer, G. M., Mian, S., & Nallasamy, N. (2024). Severe Spontaneous Tilt of Scleral-Fixated Intraocular Lenses. American Journal of Ophthalmology, 262, 206–212. https://doi.org/10.1016/j.ajo.2024.02.006
14. Friedman, S. R., Jordan, A. E., Perlman, D. C., Nikolopoulos, G. K., & Mateu-Gelabert, P. (2022). Emerging Zoonotic Infections, Social Processes and Their Measurement and Enhanced Surveillance to Improve Zoonotic Epidemic Responses: A "Big Events" Perspective. International Journal of Environmental Research and Public Health, 19(2), 995. https://doi.org/10.3390/ijerph19020995
15. Gastaldi, S., Tartari, E., Satta, G., & Allegranzi, B. (2025). Advancing infection prevention and control through artificial intelligence: A scoping review of applications, barriers, and a decision-support checklist. Antimicrobial Stewardship & Healthcare Epidemiology : ASHE, 5(1), e317. https://doi.org/10.1017/ash.2025.10191
16. Godbole, A. A., Paras, Mehra, M., Banerjee, S., Roy, P., Deb, N., & Jagtap, S. (2025). Enhancing Infection Control in ICUS Through AI: A Literature Review. Health Science Reports, 8(1), e70288. https://doi.org/10.1002/hsr2.70288
17. Huang, H., Chen, B., Wang, H.-Y., & He, M. (2016). The efficacy of daily chlorhexidine bathing for preventing healthcare-associated infections in adult intensive care units. The Korean Journal of Internal Medicine, 31(6), 1159–1170. https://doi.org/10.3904/kjim.2015.240
18. Hughes, A. M., Doos, D., Ahmed, R. A., Pham, T. N. D., & Barach, P. (2022). How Can Personal Protective Equipment Be Best Used and Reused: A Closer Look at Donning and Doffing Procedures. Disaster Medicine and Public Health Preparedness, 17, e272. https://doi.org/10.1017/dmp.2022.209
19. Liu, X., Long, Y., Greenhalgh, C., Steeg, S., Wilkinson, J., Li, H., Verma, A., & Spencer, A. (2023). A systematic review and meta-analysis of risk factors associated with healthcare-associated infections among hospitalized patients in Chinese general hospitals from 2001 to2022. The Journal of Hospital Infection, 135, 37–49. https://doi.org/10.1016/j.jhin.2023.02.013
20. Liu, Z., Dumville, J. C., Norman, G., Westby, M. J., Blazeby, J., McFarlane, E., Welton, N. J., O'Connor, L., Cawthorne, J., George, R. P., Crosbie, E. J., Rithalia, A. D., & Cheng, H. (2018). Intraoperative interventions for preventing surgical site infection: An overview of Cochrane Reviews. The Cochrane Database of Systematic Reviews, 2018(2), CD012653. https://doi.org/10.1002/14651858.CD012653.pub2
21. Lowe, H., Woodd, S., Lange, I. L., Janjanin, S., Barnet, J., & Graham, W. (2021). Challenges and opportunities for infection prevention and control in hospitals in conflict-affected settings: A qualitative study. Conflict and Health, 15(1), 94. https://doi.org/10.1186/s13031-021-00428-8
22. Luangasanatip, N., Hongsuwan, M., Limmathurotsakul, D., Lubell, Y., Lee, A. S., Harbarth, S., Day, N. P. J., Graves, N., & Cooper, B. S. (2015). Comparative efficacy of interventions to promote hand hygiene in hospital: Systematic review and network meta-analysis. https://doi.org/10.1136/bmj.h3728

23. Martignoni, M. M., Raulo, A., Linkovski, O., & Kolodny, O. (2024). SIR+ models: Accounting for interaction-dependent disease susceptibility in the planning of public health interventions. Scientific Reports, 14(1), 12908. https://doi.org/10.1038/s41598-024-63008-9
24. Martinez-Reviejo, R., Tejada, S., Jansson, M., Ruiz-Spinelli, A., Ramirez-Estrada, S., Ege, D., Vieceli, T., Maertens, B., Blot, S., & Rello, J. (2023). Prevention of ventilator-associated pneumonia through care bundles: A systematic review and meta-analysis. Journal of Intensive Medicine, 3(4), 352–364. https://doi.org/10.1016/j.jointm.2023.04.004
25. Mitra, M., Ghosh, A., Pal, R., & Basu, M. (2021). Prevention of hospital-acquired infections: A construct during Covid-19 pandemic. Journal of Family Medicine and Primary Care, 10(9), 3348–3354. https://doi.org/10.4103/jfmpc.jfmpc_742_21
26. Noto, M. J., Domenico, H. J., Byrne, D. W., Talbot, T., Rice, T. W., Bernard, G. R., & Wheeler, A. P. (2015). Chlorhexidine bathing and health care-associated infections: A randomized clinical trial. JAMA, 313(4), 369–378. https://doi.org/10.1001/jama.2014.18400
27. Paul, S., Salunkhe, S., Sravanthi, K., & Mane, S. V. (2024). Pioneering Hand Hygiene: Ignaz Semmelweis and the Fight Against Puerperal Fever. Cureus. https://doi.org/10.7759/cureus.71689
28. Ricchizzi, E., Sasdelli, E., Leucci, A. C., Fabbri, E., Caselli, L., Latour, K., Int Panis, L., De Baets, E., Van den Abeele, A.-M., D'Ambrosio, A., Kinross, P., Lehtinen, J.-M., Daniau, C., Paumier, A., Vicentini, C., Mellou, K., Salnaite, A., Weydert, M., Halonen, K., … Kärki, T. (2025). Incidence of health-care-associated infections in long-term care facilities in nine European countries: A 12-month, prospective, longitudinal cohort study. The Lancet. Infectious Diseases, 25(11), 1199–1207. https://doi.org/10.1016/S1473-3099(25)00217-8
29. Schoberer, D., Osmancevic, S., Reiter, L., Thonhofer, N., & Hoedl, M. (2022). Rapid review and meta-analysis of the effectiveness of personal protective equipment for healthcare workers during the COVID-19 pandemic. Public Health in Practice, 4, 100280. https://doi.org/10.1016/j.puhip.2022.100280
30. Scott, E. A., Bruning, E., Nims, R. W., Rubino, J. R., & Ijaz, M. K. (2020). A 21st century view of infection control in everyday settings: Moving from the Germ Theory of Disease to the Microbial Theory of Health. American Journal of Infection Control, 48(11), 1387–1392. https://doi.org/10.1016/j.ajic.2020.05.012
31. Shehab, N., Alschuler, L., McILvenna, S., Gonzaga, Z., Laing, A., deRoode, D., Dantes, R. B., Betz, K., Zheng, S., Abner, S., Stutler, E., Geimer, R., & Benin, A. L. (2024). The National Healthcare Safety Network's digital quality measures: CDC's automated measures for surveillance of patient safety. Journal of the American Medical Informatics Association: JAMIA, 31(5), 1199–1205. https://doi.org/10.1093/jamia/ocae064
32. Suzuki, A., Maeda, M., Yokoe, T., Hashiguchi, M., Togashi, M., & Ishino, K. (2021). Impact of the multidisciplinary antimicrobial stewardship team intervention focusing on carbapenem de-escalation: A single-centre and interrupted time series analysis. International Journal of Clinical Practice, 75(3), e13693. https://doi.org/10.1111/ijcp.13693
33. Tong, M. X., Hansen, A., Hanson-Easey, S., Cameron, S., Xiang, J., Liu, Q., Sun, Y., Weinstein, P., Han, G.-S., Williams, C., & Bi, P. (2015). Infectious Diseases, Urbanization and Climate Change: Challenges in Future China. International Journal of Environmental Research and Public Health, 12(9), 11025–11036. https://doi.org/10.3390/ijerph120911025
34. Wang, C.-Y., Chen, Y.-H., Hsiao, C.-C., Cheng, C.-G., & Cheng, C.-A. (2025). The Change in Healthcare-Associated Infections in Intensive Care Units Associated with the Coronavirus Disease 2019 in Taiwan. Medicina, 61(11), 1971. https://doi.org/10.3390/medicina61111971
35. Wang, Q., Han, X., Zhang, X., & Guo, L. (2025). Lean Six Sigma as a Management Tool Helps Standardize Antimicrobial Use in Hospital Settings. Drug Design, Development and Therapy, 19, 3539–3554. https://doi.org/10.2147/DDDT.S510926
36. Weber, D. J., Rutala, W. A., & Sickbert-Bennett, E. (2023). Emerging infectious diseases, focus on infection prevention, environmental survival and germicide susceptibility: SARS-CoV-2, Mpox, and

Candida auris. American Journal of Infection Control, 51(11S), A22–A34. https://doi.org/10.1016/j.ajic.2023.02.006

37. Xu, Q., Liu, Y., Cepulis, D., Jerde, A., Sheppard, R. A., Tretter, K., Oppy, L., Stevenson, G., Bishop, S., Clifford, S. P., Liu, P., Kong, M., & Huang, J. (2021). Implementing an electronic hand hygiene system improved compliance in the intensive care unit. American Journal of Infection Control, 49(12), 1535–1542. https://doi.org/10.1016/j.ajic.2021.05.014
38. Yerramilli, P., Chopra, M., & Rasanathan, K. (2024). The cost of inaction on health equity and its social determinants. BMJ Global Health, 9(Suppl 1), e012690. https://doi.org/10.1136/bmjgh-2023-012690